Invention Grant
- Patent Title: 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
-
Application No.: US17464166Application Date: 2021-09-01
-
Publication No.: US12030873B2Publication Date: 2024-07-09
- Inventor: Paul Anthony Baguley , Colin Thomas Lindley , Robert Craig Melling
- Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
- Applicant Address: JP Tokyo
- Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
- Current Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
- Current Assignee Address: JP Tokyo
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: GB 06327 2017.04.20
- Main IPC: C07D405/14
- IPC: C07D405/14 ; A61K9/00 ; A61K9/19 ; A61K9/20 ; A61K9/48 ; A61K47/10

Abstract:
This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
Public/Granted literature
- US20220169638A1 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR Public/Granted day:2022-06-02
Information query